

Content

CHAPTER #	TOPIC	PAGE #
	CERTIFICATE OF APPROVAL	iv
	DEDICATION	vi
	CONTENT	vii
	LIST OF FIGURES	xii
	LIST OF TABLES	xvi
	LIST OF ABBREVIATIONS	xxi
	ACKNOWLEDGEMENT	xxiii
	ABSTRACT	xxiv
1	INTRODUCTION	1
1.1	Oral Drug Delivery Systems	1
1.2	Anatomical and Physiological Consideration of GIT	3
1.2.1	The Oesophagus	5
1.2.2	The Stomach	6
1.2.3	The Small Intestine	7
1.2.4	The Colon	9
1.3	Drug Absorption form GIT	10
1.4	Modified Drug Delivery System	12
1.4.1	Types of Modified Drug Delivery Systems	13
1.4.1.1	Delayed or Repeated Release Dosage Forms	13
1.4.1.2	Prolonged or Extended Release Dosage Forms	13
1.4.1.3	Targeted Release Dosage Forms	14
1.4.2	Requirements for Candidate for Oral Controlled Released Dosages Form	14
1.4.2.1	Drug Dissolution	14
1.4.2.2	Solubility and pKa	15
1.4.2.3	Absorption	16
1.4.2.4	Distribution	17
1.4.2.5	Elimination and Clearance	18
1.4.2.6	Routine Binding	19
1.4.2.7	Elimination Half-life	20
1.4.3	Oral Controlled Release Matrix Systems	21
1.4.3.1	Advantages and Disadvantages of Oral Controlled Released Matrix Systems	22
1.4.3.2	Controlled Released Matrix Tablets	24
1.4.3.3	Lipid Matrix Systems	27
1.4.3.4	Insoluble Polymer Matrix Systems	28

1.4.4	Reservoir Systems	29
1.4.5	Other Technologies	30
1.4.5.1	Multi-Particulate Formulation	30
1.4.5.2	Phased Drug Delivery	30
1.4.5.3	Ion-Exchange Systems	31
1.4.5.4	Bioadhesive	32
1.4.5.5	Gastroretentive Systems	32
1.5	Model Drugs	33
1.5.1	Flurbiprophen	33
1.5.2	Dicolofenac Sodium	34
1.6	Controlled Released Polymers	35
1.6.1	Cellulose Derivative Polymers Used for Drug Delivery	36
1.7	Tablet Preparation	38
1.7.1	Direct Compression	38
1.7.2	Advantages of Direct Compression	39
1.7.3	Limitation of Direct Compression	39
1.8	<i>In-Vitro</i> Evaluation	39
1.8.1	Bioavailability-Bioequivalence Studies	40
1.8.2	Absolute Bioavailability	41
1.8.3	Relatives Bioavailability	41
1.8.4	Direct Method	42
1.8.5	In-Direct Method	42
1.9	High Performance Liquid Chromatographic Analysis	44
1.9.1	Method Validation	44
1.9.2	Linearity	45
1.9.3	Precision	45
1.9.4	Repeatability or Intra-day Precision	46
1.9.5	Intermediate Decision or Inter-day Precision	46
1.9.6	Reproducibility	46
1.9.7	Accuracy	46
1.9.8	Limit of Quantitation (LOQ) / Limit of Detection (LOD)	47
1.10	Aims of the Work	47
2	REVIEW OF LITERATURE	48
3	MATERIALS AND METHODS	64
3.1	Materials	64
3.2	Equipments	64
3.3	Methods	66
3.3.1	Particle Size Analysis	66

3.3.2	Particle Size Distribution	66
3.3.3	UV Spectrophotometric Analysis	66
3.3.3.1	Selection of Suitable Wavelength	66
3.3.3.2	Standard Curve of FLB and DCL –Na	67
3.3.4	Pre-Formulation Study	67
3.3.4.1	Equilibrium Solubility	67
3.3.4.2	Preparation of Solid Dispersion	67
3.3.4.3	Bulk Density	68
3.3.4.4	Tapped Density	68
3.3.4.5	Hausner's Ratio	69
3.3.4.6	Angle of Repose	69
3.3.4.7	Compressibility Index	70
3.3.5	Differential Scanning Calorimetry	70
3.3.6	Infra-Red Absorption spectroscopy	71
3.3.7	Scanning Electron Microscopy	71
3.3.8	X-Ray Diffractometry	71
3.3.9	Preparation of Matrix Tablets	71
3.3.9.1	Preparation of 100 mg each of FLV and DCL-Na Tablets	71
3.3.9.2	Preparation of 100 mg each of FLV and DCL-Na Tablets without Polymer	76
3.3.9.3	Preparation of 200 mg each of FLV Tablets	77
3.3.10	Physical Characterises of Matrix Tablets	77
3.3.10.1	Thickness and Diameter	77
3.3.10.2	Hardness	78
3.3.10.3	Weight Variation	78
3.3.10.4	Friability Test	79
3.3.10.5	Content Uniformity Test	80
3.3.11	<i>In-Vitro</i> Drug Release Study	80
3.3.12	Drug Release Kinetics	81
3.3.12.1	Zero-Order Kinetics	82
3.3.12.2	First-Order Kinetics	82
3.3.12.3	Hixson Crowell's Equation or Erosion Model	82
3.3.12.4	Higuchi's Kinetics	83
3.3.12.5	Krosmeyer-Peppas Equation	83
3.3.13	Polymer Hydration or Water Uptake	84
3.3.14	Matrix Erosion	85
3.3.15	Testing Dissolution Equivalency	85
3.3.16	Effect of Aging on the Release of FLV and DCL-Na from Controlled Released Matrix Tablets	86

3.3.17	High Performance Liquid Chromatography (HPLC) Method Development	87
3.3.17.1	Preparation of HPLC analytical Method	87
3.3.17.2	Precision and Accuracy	87
3.3.17.3	Limit of Detection and Limit of Quantitation	88
3.3.17.4	Specificity	88
3.3.18	<i>In-vivo</i> Studies	89
3.3.18.1	Study Protocol and Design	89
3.3.18.2	Selection of Animals	89
3.3.18.3	Animal Housing and Maintaining	89
3.3.18.4	Dose Administration	90
3.3.18.5	Collection of Blood Samples	90
3.3.18.6	Extraction of Drug from Serum	90
3.3.18.7	Preparation of Standard Curve	91
3.3.18.8	Analysis of FLV and BCL-Na	92
3.3.18.9	Pharmacokinetic Analysis	92
3.3.19	<i>In-Vitro In-vivo</i> Co-Relation	92
3.3.20	Statistical Analysis	92
4	RESULTS AND DISCUSSION	93
4.1	Particle Size Analysis	93
4.2	Particle Size Distribution	94
4.3	UV Spectrophotometric Analysis	98
4.3.1	Selection of Suitable Wavelength	98
4.3.2	Standard Curve of FLB and DCL –Na	100
4.4	Pre-Formulation Study	102
4.4.1	Equilibrium Solubility	102
4.4.2	Preparation of Solid Dispersion	103
4.4.3	Bulk Density	104
4.4.4	Tapped Density	104
4.4.5	Hausner's Ratio	105
4.4.6	Angle of Repose	106
4.4.7	Compressibility Index	106
4.7	Differential Scanning Calorimetry	111
4.8	Infra-Red Absorption spectroscopy	112
4.9	Scanning Electron Microscopy	114
4.10	X-Ray Diffractometry	123
4.11	Preparation of Matrix Tablets	124
4.12	Physical Characterises of Matrix Tablets	125
4.12.1	Thinks and Diameter	126

4.12.2	Hardness	126
4.12.3	Friability	126
4.12.4	Weight Variation	127
4.12.5	Content Uniformity	127
4.13	<i>In-Vitro</i> Drug Release Study	131
4.13.1	Release of Drug from tablets prepared without polymer	131
4.13.2	Effect of Ethocel® Viscosity Grade	132
4.13.3	The Effect of Drug to Polymer Ratios	134
4.13.4	Ethocel® Std: Premium vs. Ethocel® Std: FP Premium	135
4.13.5	Effect of Partial Replacement of HPMC	136
4.13.6	Effect of Partial Replacement of CMC	139
4.13.7	Effect of Partial Replacement of Starch	141
4.13.8	Release of Drug from Solid dispersions Tablets	144
4.14	Drug Release Kinetics	146
4.15	Polymer Hydration or Water Uptake	156
4.16	Matrix Erosion	159
4.17	Testing Dissolution Equivalency	160
4.18	Effect of Aging on the Release of FLB and DCL-Na from Controlled Released Matrix Tablets	161
4.19	High Performance Liquid Chromatography (HPLC) Method Development	163
4.19.1	Preparation of HPLC analytical Method	163
4.19.2	Precision and Accuracy	163
4.19.3	Limit of Detection and Limit of Quantitation	164
4.19.4	Specificity	164
4.20	<i>In-vivo</i> Studies and Pharmacokinetics Analysis	169
4.21	<i>In-vitro In-vivo</i> Co-Relation	174
5	CONCLUSION	178
6	FUTURE PROSPECTS	179
7	LIST OF PUBLICATIONS	180
8	REFERENCES	182